International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic

Victor Ho Fun Lee*, Marlinda Adham, Wala Ben Kridis, Paolo Bossi, Ming Yuan Chen, Imjai Chitapanarux, Vincent Gregoire, Sheng Po Hao, Cheryl Ho, Gwo Fuang Ho, Danita Kannarunimit, Dora Lai Wan Kwong, Ka On Lam, Wai Kei Jacky Lam, Quynh Thu Le, Anne Wing Mui Lee, Nancy Y. Lee, To Wai Leung, Lisa Licitra, Darren Wan Teck LimJin Ching Lin, Kwok Seng Loh, Pei Jen Lou, Jean Pascal Machiels, Hai Qiang Mai, Ricard Mesía, Wai Tong Ng, Roger Kai Cheong Ngan, Joshua K. Tay, Raymond King Yin Tsang, Chi Chung Tong, Hung Ming Wang, Joseph T. Wee

*此作品的通信作者

研究成果: 期刊稿件文獻綜述同行評審

8 引文 斯高帕斯(Scopus)

摘要

The effects of the COVID-19 pandemic continue to constrain health-care staff and resources worldwide, despite the availability of effective vaccines. Aerosol-generating procedures such as endoscopy, a common investigation tool for nasopharyngeal carcinoma, are recognised as a likely cause of SARS-CoV-2 spread in hospitals. Plasma Epstein-Barr virus (EBV) DNA is considered the most accurate biomarker for the routine management of nasopharyngeal carcinoma. A consensus statement on whether plasma EBV DNA can minimise the need for or replace aerosol-generating procedures, imaging methods, and face-to-face consultations in managing nasopharyngeal carcinoma is urgently needed amid the current pandemic and potentially for future highly contagious airborne diseases or natural disasters. We completed a modified Delphi consensus process of three rounds with 33 international experts in otorhinolaryngology or head and neck surgery, radiation oncology, medical oncology, and clinical oncology with vast experience in managing nasopharyngeal carcinoma, representing 51 international professional societies and national clinical trial groups. These consensus recommendations aim to enhance consistency in clinical practice, reduce ambiguity in delivering care, and offer advice for clinicians worldwide who work in endemic and non-endemic regions of nasopharyngeal carcinoma, in the context of COVID-19 and other airborne pandemics, and in future unexpected settings of severe resource constraints and insufficiency of personal protective equipment.

原文英語
頁(從 - 到)e544-e551
期刊The Lancet Oncology
23
發行號12
DOIs
出版狀態已出版 - 12 2022

文獻附註

Publisher Copyright:
© 2022 Elsevier Ltd

指紋

深入研究「International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic」主題。共同形成了獨特的指紋。

引用此